| Advanced Periodontics | |
|
1420 N. Arlington Hts. Rd. #110 Arlington Hts. IL 60004 | |
| (847) 255-3021 | |
| Not Available |
| Full Name | Advanced Periodontics |
|---|---|
| Speciality | Dentist - Periodontics |
| Location | 1420 N. Arlington Hts. Rd. #110, Arlington Hts., Illinois |
| Authorized Official Name and Position | Linda Kardos (PRACTICE MANAGER) |
| Authorized Official Contact | 8472553021 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Advanced Periodontics 1420 N. Arlington Hts. Rd. #110 Arlington Hts. IL 60004 Ph: (847) 255-3021 | Advanced Periodontics 1420 N. Arlington Hts. Rd. #110 Arlington Hts. IL 60004 Ph: (847) 255-3021 |
| NPI Number | 1639397995 |
|---|---|
| Provider Enumeration Date | 04/23/2007 |
| Last Update Date | 08/22/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639397995 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223P0300X | Dentist - Periodontics | 19015917 (Illinois) | Primary |
News Archive
Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.
"Niger arrested about 20 doctors suspected of embezzling funds from a charity promoting vaccination in poor countries, ... judicial and police sources said on Monday," Reuters reports.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it is planning to expand the development of Gencaro, its lead cardiovascular drug candidate, to atrial fibrillation, a disease that affects more than 2.4 million patients in the United States.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
​Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 7 days ago